ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Merck To Test Cancer Drug With Rivals …

by Michael McCoy
February 10, 2014 | APPEARED IN VOLUME 92, ISSUE 6

Merck & Co. has signed clinical research pacts with three rival companies to evaluate combinations of their drugs with MK-3475, a Merck antibody in development as a cancer immunotherapy. Merck will study MK-3475 in combination with Pfizer’s small-molecule kinase inhibitor Inlyta. The firm will investigate a combination of MK-3475 with Incyte’s investigational immunotherapy INCB24360. And Merck will test its drug with talimogene laherparepvec, an Amgen drug now in development. FDA dubbed MK-3475 a breakthrough therapy last year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment